The structure and function of bone tissue is maintained through a constant remodeling process, which is maintained by the balance between osteoblasts and osteoclasts. The failure of bone remodeling can lead to pathological conditions of bone structure and function. Remifentanil is currently used as a narcotic analgesic agent in general anesthesia and sedation. However, the effect of remifentanil on osteoclasts has not been studied. Therefore, we investigated the effect of remifentanil on pre-osteoclast (pre-OCs) differentiation and the mechanism of osteoclast differentiation in the absence of specific stimulus. Methods: Pre-OCs were obtained by culturing bone marrow-derived macrophages (BMMs) in osteoclastogenic medium for 2 days and then treated with various concentration of remifentanil. The mRNA expression of NFATc1 and c-fos was examined by using real-time PCR. We also examined the effect of remifentanil on the osteoclast-specific genes TRAP, cathepsin K, calcitonin receptor, and DC-STAMP. Finally, we examined the influence of remifentanil on the migration of pre-OCs by using the Boyden chamber assay. Results: Remifentanil increased pre-OC differentiation and osteoclast size, but did not affect the mRNA expression of NFATc1 and c-fos or significantly affect the expression of TRAP, cathepsin K, calcitonin receptor, and DC-STAMP. However, remifentanil increased the migration of pre-OCs. Conclusions: This study suggested that remifentanil promotes the differentiation of pre-OCs and induces maturation, such as increasing osteoclast size. In addition, the increase in osteoclast size was mediated by the enhancement of pre-OC migration and cell fusion.
INTRODUCTION
The structure and function of bone is regulated through bone remodeling, which occurs in microscopic basic multicellular units (BMU) that consist of bone-forming osteoblasts, bone-resorbing osteoclasts, and osteocytes within the bone matrix, the bone lining cells that cover the bone surface and the capillary blood supply [1, 2] .
The bone remodeling cycle is composed of three phases: initiation, reversal, and termination. The initiation phase includes the migration of osteoclast precursors to the bone surface, their differentiation into mature osteoclasts, and the maintenance of bone resorption. The reversal phase is a transition from osteoclast to osteoblast activity. The final stage is the termination phase, in which bone formation by osteoblasts occurs [3, 4] . An imbalance in bone remodeling can result in an excess of bone resorption compared with bone formation, which may lead to the occurrence of pathologic states of bone structure, such as osteoporosis.
Osteoclasts are a key participant in bone remodeling.
Located on endosteal surfaces within the Haversian system and on the periosteal surface beneath the periosteum, these are multinucleated, giant cells formed by the fusion of mononuclear progenitors of the monocyte/macrophage family by osteoclastogenesis [5, 6] .
For osteoclastogenesis, macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor kappa B ligand (RANKL) are required. These molecules induce the expression of osteoclastogenic genes, such as tartrate-resistance acid phosphatase (TRAP), cathepsin K (CTK), calcitonin receptor (CTR), and β3-integrin, which lead to the formation of mature osteoclasts [7] . Cell fusion in the osteoclast lineage is necessary for the formation of mature osteoclasts (also known as multinucleated osteoclasts). The main effect of osteoclast multinucleation is an increase in the size of osteoclasts, which causes their activation and stimulates the resorption of larger bone tissue [8, 9] . Therefore, osteoclastogenic cell fusion is an essential component of the process of osteoclastogenesis. Many molecules involved in osteoclastogenic cell fusion have been reported, including macrophage fusion receptor, signal regulatory protein α, and dendritic cell-specific transmembrane protein (DC-STAMP) [10, 11] .
Remifentanil is a short-acting μ-opioid receptor agonist that is rapidly hydrolyzed by nonspecific esterases in plasma and tissue; even when administered as a prolonged infusion, it does not accumulate. Therefore, it can be administered via continuous infusion during general anesthesia and sedation in the intensive care unit (ICU) [12, 13] . During orthognathic surgery or prolonged sedation in ICU, the continuous infusion of remifentanil may affect the bone physiology of the patient, because the patients who undergo orthognathic surgery or are treated in the ICU are more likely to have pathologic bone disease or to be elderly. The effects of remifentanil on osteoblasts have been previously studied. It was recently reported that remifentanil has a protective effect against oxidative stress on human osteoblasts [14] . Baik et al. [15] determined that remifentanil preconditioning enhanced the maturation of osteoblasts under hypoxia-reoxygenation conditions and increased the expression of osteoblastogenic genes.
However, the effects of remifentanil on osteoclast differentiation have not been reported. Therefore, we investigated the effects of remifentanil on osteoclast differentiation and osteoclastogenic gene expression through the in vitro examination of pre-osteoclasts.
MATERIALS AND METHODS

Reagents
Remifentanil was obtained from GlaxoSmithKline 
Pre-osteoclast (pre-OC) differentiation and remifentanil treatment
The differentiation of pre-OCs, mononuclear TRAP- the formation of the blue formazan product was measured at 570 nm by using a microplate reader.
TRAP staining
The cells were fixed in 3.7% formalin for 10 min, 
Real-time polymerase-chain reaction (PCR) analysis
Total RNA was isolated by using TRIzol reagent 
Boyden chamber migration assay
Transwells with 8 µm porosity polycarbonate membrane inserts were used. Pre-OCs were suspended in α Fig. 1 . Remifentanil does not affect the cytotoxicity or cell proliferation of pre-osteoclasts (pre-OCs). (A) Pre-OCs were incubated in medium containing the indicated concentrations of remifentanil (0-100 ng/ml) for 24 h. Cell viability was evaluated by using the MTT assay, (B) Pre-OCs were cultured in osteoclastogenic medium (30 ng/ml M-CSF + 100 ng/ml RANKL) for 3 days in the absence or presence of remifentanil (up to 100 ng/ml). Cell proliferation was measured by using the MTT assay.
-MEM media at 1×10 5 cells/100 µl and were added to the upper chamber. Remifentanil (10 and 50 ng/ml) in α-MEM media was added into the lower chamber.
Pre-OCs that migrated through the filter and appeared on the lower side were fixed by careful immersion of the filter into methanol for 1 min, stained with hematoxylin and eosin (H&E) solution, and counted in three random fields per well. Each experiment was performed in duplicate and three separate experiments were performed for each treatment group.
Statistical analysis
Data were obtained from at least three independent experiments. Student's t-test was used to determine the significance of differences between two groups. Differences with P < 0.01 were regarded as statistically significant and denoted with an asterisk ( ** P < 0.01; *** P < 0.001).
RESULTS
Remifentanil was not cytotoxic to pre-OCs and did not increase cell proliferation
BMMs were cultured with OM for 2 days to induce differentiation to pre-OCs (Fig. 1A) . The effect of remifentanil on the cell viability and proliferation of pre-OCs was verified by using an MTT assay. The MTT assay indicated that the cell viability of pre-OCs was not affected by treatment with various concentrations of remifentanil (0.1, 1, 10, and 100 ng/ml) (Fig. 1B) . The proliferation of pre-OCs cultured in OM for 3 days with remifentanil was maintained and no significant difference in cell proliferation was identified at different remifentanil concentrations (Fig. 1B) .
Remifentanil increased pre-OC differentiation and the size of osteoclasts cultured with M-CSF and RANKL
Pre-OCs were cultured with M-CSF alone or OM in the presence of remifentanil for 2-3 days to evaluate the formation of mature osteoclasts. TRAP staining was used for this analysis; TRAP-positive multinucleated cells with ≥ 3 nuclei were considered to be mature osteoclasts.
Remifentanil increased the formation of TRAP-positive multinucleated osteoclasts, especially after 3 days ( Fig.   2A ). The size of osteoclasts was significantly increased by the presence of remifentanil (50 ng/ml) compared with the absence of remifentanil (Fig. 2B) . These results confirmed that the administration of remifentanil to pre-OCs enhanced osteoclast differentiation and maturation.
The mRNA expression of NFATc1 and c-fos was not affected by remifentanil treatment
NFATc1, a member of the NFAT family of transcrip- by an increase in the dose of remifentanil (0, 10, and 50 ng/ml) during osteoclastogenesis (Fig. 3A, B) . These results confirmed that the enhancement of pre-OC differentiation by remifentanil was not mediated by the activation of NFATc1 and c-fos.
Remifentanil did not induce the expression of osteoclast-specific genes such as TRAP, CTK, CTR, and DC-STAMP
TRAP, CTK, and CTR are osteoclast differentiation marker genes that are induced by NFATc1 activation at the final stage of differentiation [19] . As previous results
showed that remifentanil upregulated pre-OC differentiation ( Fig. 2A, B) , we hypothesized that remifentanil may increase the expression of osteoclast-specific genes. The mRNA expression of osteoclastogenic-specific genes was analyzed in pre-OCs. As shown in Fig. 4A , B, and C, the relative mRNA expression of TRAP, CTK, and CTR was not significantly increased for remifentanil treatment 5 . The migration of pre-osteoclasts (pre-OCs) was evaluated by using a Boyden chamber assay. (A) Pre-OCs in DMEM were added to the upper chamber and remifentanil (10 and 50 ng/ml) in DMEM was added into the lower chamber. The pre-OCs that migrated to the lower chamber were fixed and stained with hematoxylin and eosin solution, (B) The number of migrated cell numbers were counted. All quantitative data are the mean ± SD of three independent experiments (***, P < 0.001).
(10 and 50 ng/ml) compared with the presence of only M-CSF and RANKL on days 2 and 4.
DC-STAMP is a key regulator in osteoclast cell-cell fusion, which is a critical process for osteoclast maturation [20] . To investigate the relationship of cell-cell fusion with the upregulation of pre-OC differentiation induced by remifentanil, the mRNA expression of DC-STAMP was evaluated. Treatment with remifentanil increased the relative mRNA expression of DC-STAMP in a dose-dependent manner after 4 days, but the difference was not significant (Fig. 4D) .
Remifentanil enhanced pre-OC migration
The migration of pre-OCs was evaluated by using the Boyden chamber assay. Pre-OCs in medium were seeded in the upper part of a Transwell plate and allowed to migrate vertically through the pores of the membrane into the lower chamber, which held the control or remifentanil-containing medium. The number of migrated cells was increased after remifentanil treatment (10 and 50 ng/ml) in the lower chamber compared with the control (Fig. 5A ). In addition, the number of migrated cells was significantly increased by 50 ng/ml remifentanil compared with the untreated control (Fig. 5B ).
DISCUSSION
In this study, we evaluated the effects of remifentanil Cell fusion is a characteristic properties of osteoclasts.
Through this process, osteoclasts become multinucleated, increase in size, and are able to absorb bone [8] . In this study, the mRNA expression of DC-STAMP, a key protein for cell fusion in osteoclast, was not upregulated by remifentanil. This suggested that the increase in size of osteoclasts induced by remifentanil was not mediated by the upregulation of DC-STAMP. Cell fusion also can be enhanced by cell migration [24] . Therefore, we assessed the effect of remifentanil on pre-OC migration by using a Boyden chamber assay. The results showed that remifentanil enhanced pre-OC migration. These findings suggested pre-OC migration enhanced cell fusion, which resulted in an increase in osteoclast size.
In a previous in vitro study, remifentanil suppressed the formed [25] . In previous study, the effects of remifentanil on osteoclast differentiation were investigated in BMMs.
However, in this study, we added remifentanil to pre-OCs and evaluated osteoclast differentiation and other parameters. Contrasting results of osteoclast differentiation have been reported. A recent report stated that lipopolysaccharide (LPS) promoted osteoclast differentiation; in this study, LPS was added during the process of osteoclast differentiation after M-CSF and RANKL treatment [26] .
In another study, LPS treatment to BMMs inhibited RANKL activity and subsequently decreased osteoclast differentiation [27] . Therefore, the effects of remifentanil on osteoclast differentiation may differ according to the stage of the differentiated osteoclasts treated with remifentanil.
In summary, we found that remifentanil increased pre-OC differentiation and the size of osteoclasts. In addition, we demonstrated that the remifentanil-induced increase in osteoclasts was mediated through the enhancement of pre-OC migration and cell fusion.
